{"prompt": "['Post-', 'Long-term', 'Treatment', 'Follow-up', 'Trial Phase:', 'Pre-treatment Phase', 'Treatment Phaseb', 'Phase', 'Phase', 'Screening', 'Baseline', 'Treatment Cycle/Title:', '(Visit 1 )a,b', '(Visit 2) a,b', '1', '2', '3', '4', 'Within 14', 'days of last', 'Every 12', 'dose of', 'weeks +/- 14', 'Day:', '-28 to 1', '-3 to 1', '1', '8', '15', '22', '29', '36', '43', '50', '57', '64', '71', '78', 'lenvatinib', 'days', 'c.', 'Long-term', \"follow-up should continue until the patient's withdrawal of consent or loss to follow up, death, or study termination. Patients in long term follow-up can be\", 'seen by medical oncology or urology team, have chart reviewed, or phone call to determine current status every 12 weeks.', 'd.', 'Concomitant meds are recorded for 30 days after last dose', 'e.', 'Assessments will include vital signs (resting BP, HR, RR, and body temperature), weight, and height. Height will be measured at the Screening Visit only. Elevated BP', 'assessment (i.e., systolic BP >140 mmHg or diastolic BP >90 mmHg) should be confirmed by a repeat assessment after a minimum of 1 hour. One BP assessment is', 'defined', 'as', 'the', 'mean', 'value of 3 measurements at least 5 minutes apart. Subjects with systolic BP >160 mmHg or diastolic BP >100 mmHg must have their BP monitored', 'every 2 weeks until systolic BP has been <150 mmHg and diastolic BP has been <95 mmHg for 3 consecutive months. If a new event of systolic', 'BP', 'I>160', 'mmHg', 'or', 'diastolic BP >100 mmHg occurs, the subject must resume the evaluation every 2 weeks until systolic BP has been 150 mmHg and diastolic', 'BP', 'has', 'been', '<95', 'mmHg', 'for', '3 consecutive months.', 'f.', 'Appendix 1', 'g.', 'If clinically indicated', 'h.', 'Sarcopenia assessment will be completed using baseline and post-week 12 archival scans via SliceOmatic v5.0 by TomoVision program after', 'completion', 'of', 'study.', 'i.', 'Appendix 4', 'j.', 'Appendix 5', 'k.', 'Only necessary in women of child bearing potential', '1.', 'Clinical laboratory tests include a standard hematology panel (WBC with differential [including absolute count of neutrophils, basophils,', 'eosinophils,', 'lymphocytes,', 'monocytes at minimum], hemoglobin/hematocrit, platelet count), chemistry panel (albumin, alkaline phosphatase, ALT, amylase, AST, bicarbonate,', 'bilirubin,', 'blood', 'urea', 'nitrogen,', 'calcium, chloride, creatinine, y-glutamyltransferase [GGT], glucose, lactate dehydrogenase, lipase, magnesium, phosphorus, potassium, sodium, total protein,', 'uric acid), and CRP', 'm.', 'As per standard of care while initiating lenvatinib, transaminases including AST and ALT need to be monitored every 2 weeks for the first 2 months of treatment. For this', 'reason, the patient will have these checked at the time of each cycle start but also between days 8 and 15, days 29 and 36, and days 50 and 57 (This test can', 'be', 'done', 'by', 'locally if patient is traveling).', 'n.', 'Urinalysis includes appearance, color, pH, specific gravity, ketones, protein, UPCR, glucose bilirubin, nitrite, creatinine, urobilinogen, occult blood (microscopic', 'examination of sediment will be performed only if the results of the urinalysis dipstick evaluation are positive)', 'o.', 'If urine dipstick has >2+ proteinuria, a 24-hour urine collection will be collected for protein quantification and adverse effect grading', '38']['Post-', 'Long-term', 'Treatment', 'Follow-up', 'Trial Phase:', 'Pre-treatment Phase', 'Treatment Phaseb', 'Phase', 'Phase', 'Screening', 'Baseline', 'Treatment Cycle/Title:', '(Visit 1 )a,b', '(Visit 2) a,b', '1', '2', '3', '4', 'Within 14', 'days of last', 'Every 12', 'dose of', 'weeks +/- 14', 'Day:', '-28 to 1', '-3 to 1', '1', '8', '15', '22', '29', '36', '43', '50', '57', '64', '71', '78', 'lenvatinib', 'days', 'p.', 'Screening brain scans will be performed by MRI pre- and post- gadolinium within 28 days prior to C1D1. During the Treatment Phase, CT/MRI of the brain will be', 'performed if clinically indicated', 'q.', 'Screening tumor assessments using CT of the chest can be done with or without IV iodinated contrast', 'r.', 'Screening and post-treatment tumor assessments of the abdomen pelvis can be done with MRI or CT. CT should be performed with iodinated IV contrast and MRI scans', 'should be done with IV gadolinium chelate unless there is a medical contraindication to contrast.', 'S.', 'An archival tumor tissue sample must be available prior to first dose. If an archival tumor sample for biomarker analysis is not available, then a newly obtained tumor', 'biopsy must be obtained prior to the first dose. Subjects must have recovered adequately from the biopsy prior to starting therapy.', 't.', 'Patients will undergo kidney surgery a minimum 7 days after the last dose of lenvatinib', 'u.', 'Analysis of intraoperative and post-operative complications using the universally used Clavien-Dindo perioperative classification of adverse events [1]', 'V.', 'Blood for correlative studies will be collected in the post-treatment phase both before and after nephrectomy', '39']\n\n###\n\n", "completion": "END"}